FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 474 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis May 25, 2023 A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials May 7, 2019 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then... May 13, 2019 FDA Oversight of E-Cigarettes Gathers Speed: A Conversation with Mitch Zeller January 5, 2022 Load more HOT NEWS Factors Associated with COVID-19 Severity Among Patients with Cancer Bagel Shop Owner Shaves Head To Support 10-Year-Old Customer Drinking Alcohol, Often Heavily, Common among People with Cancer and Long-Term... FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory...
